Important: New Login Process

We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.

  • If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
  • If you log in with a username and password, you will be prompted to set a new password before accessing your account.

Go to the Login Page to get started.

We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.

BioCentury
ARTICLE | Clinical News

Gilead’s selonsertib fails Phase III for NASH compensated cirrhosis

February 12, 2019 12:01 AM UTC

Gilead Sciences Inc. (NASDAQ:GILD) said selonsertib (GS-4997) missed the primary endpoint in the Phase III STELLAR-4 trial to treat compensated cirrhosis due to non-alcoholic steatohepatitis (NASH). Selonsertib is an oral small molecule ASK1 inhibitor.

The primary endpoint measured the percent of patients who achieved a histologic improvement in fibrosis of at least one stage according to the NASH Clinical Research Network (CRN) classification without worsening of NASH after 48 weeks of treatment. Among 877 adults enrolled, 12.5% of patients that received 6 mg once-daily selonsertib (p=1) and 14.4% of patients dosed with 18 mg once-daily selonsertib achieved the endpoint vs. 12.8% of patients that received placebo...

Get Unlimited Access
Continue reading with a free trial.
Or Purchase This Article